Table of Contents
In recent years, SGLT2 inhibitors have become an integral part of diabetes management. They offer a unique mechanism of action by promoting glucose excretion through the kidneys, which helps improve glycemic control and provides additional cardiovascular and renal benefits.
Understanding SGLT2 Inhibitors
SGLT2 inhibitors, also known as sodium-glucose co-transporter 2 inhibitors, include medications such as empagliflozin, dapagliflozin, and canagliflozin. These drugs work by blocking the SGLT2 protein in the proximal tubules of the kidneys, reducing glucose reabsorption, and increasing urinary glucose excretion.
Indications for Use
SGLT2 inhibitors are primarily prescribed for adults with type 2 diabetes who require additional glycemic control. They are also indicated for patients with established cardiovascular disease or chronic kidney disease to reduce the risk of adverse cardiovascular and renal outcomes.
Guidelines for Prescribing
When considering SGLT2 inhibitors, clinicians should evaluate patient-specific factors, including renal function, risk of genital infections, and cardiovascular status. Proper patient selection is essential to maximize benefits and minimize risks.
Assessing Renal Function
Before initiating therapy, check estimated glomerular filtration rate (eGFR). SGLT2 inhibitors are contraindicated in patients with significantly impaired renal function, typically eGFR below 45 mL/min/1.73 m², depending on the specific medication.
Monitoring and Follow-up
Regular monitoring of renal function, blood glucose levels, and signs of urinary tract or genital infections is crucial during treatment. Adjust therapy based on patient response and tolerability.
Precautions and Contraindications
SGLT2 inhibitors are generally well-tolerated but can cause side effects such as dehydration, hypotension, and increased risk of infections. They are contraindicated in patients with active genital infections, severe renal impairment, or hypersensitivity to the drug.
Conclusion
Guidelines for prescribing SGLT2 inhibitors emphasize careful patient selection, regular monitoring, and awareness of potential side effects. When used appropriately, these medications can significantly enhance diabetes care by improving glycemic control and reducing cardiovascular and renal risks.